

Artificial Intelligence in Cancer Diagnostics: Clinical Performance, Workflow Impact, and Future Directions

Shanza Tariq¹, Hamna Majeed², Muhammad Arslan Shabbir³, Huda Abbas⁴, Maheen Rehan⁵

¹ Instructor at Avicenna Medical and Dental College, Lahore Email: tariqshanza16@gmail.com

² Forman Christian College University (FCCU), Lahore Email: hamnamajeed22@gmail.com

³ Forman Christian College University (FCCU), Lahore Email: arslanshabbir790@gmail.com

⁴ Forman Christian College University (FCCU), Lahore Email: hudaabbasjoiya27@gmail.com

⁵ Forman Christian College University (FCCU), Lahore Email: maheenrehan2216@gmail.com

DOI: <https://doi.org/10.63163/jpehss.v3i3.534>

Abstract:

A subset of artificial intelligence (AI), deep learning (DL) is rapidly transforming cancer detection. This review explores how artificial intelligence can enhance digital pathology's repeatability, workflow efficiency, and diagnostic accuracy by means of data integration from several studies evaluating AI systems for different tumors types. Designed to find melanoma, prostate cancer, and breast cancer metastases, artificial intelligence (AI) tools outperform human experts either exactly or slightly. Moreover, systematic reviews and reproducibility models in existence call for the imperative necessity of standardized assessment and judicious integration into clinical protocols. Despite the breakthroughs achieved, numerous issues with regard to clinical interpretability, generalizability, and ethical utilization persist and remain of major concern. Besides advancing accuracy in medical evaluations, the deployment of artificial intelligence in cancer diagnosis also has the potential to diminish healthcare disparities considerably, particularly in underdeveloped or under-resourced areas. As artificial intelligence platforms evolve and enhance themselves, the prospect of them playing a positive role in patient outcomes and healthcare processes becomes more evident and realized. It should be noted, however, that oncology artificial intelligence technologies are still in their infancy stage of evolution; thus, their safe and effective use in clinical environments is contingent on rigorous validation processes and judicious consideration of ethical implications. The aim of this paper is to examine the evolving role of artificial intelligence in oncologic diagnostics, as well as in-depth analysis of its current strengths and weaknesses, benefits, and strategic long-term guidance that is necessary to facilitate stable, scalable, and equitable clinical adoption.

Keywords: Artificial intelligence (AI), deep learning (DL), Cancer

1. Introduction:

Artificial intelligence, also known as AI, is quickly becoming an essential and integral part of the discipline of cancer diagnosis. With medical data and knowledge changing rapidly and growing more complex, AI leveraging the innovative power of artificial neural networks (ANNs)—is delivering crucial analytical insights that are improving diagnostic processes. These ANNs, through their multilayer architecture and sophisticated kinds of supervised learning, have greatly enhanced cancer detection accuracy. Possibly the most impressive feature of ANNs is that they can handle enormous amounts of data and determine complex patterns that can easily go unnoticed by the human senses and thus convert unstructured medical images into structured, usable information. This breakthrough technology is truly revolutionizing the discipline of oncological diagnosis, making it possible to detect accurate tumor localization, gene mutation, and continuous monitoring of treatment response, all of which are of crucial importance in effective cancer management.(1)

Cancer is a worldwide public health issue and, as such, an emergent topic that necessitates global attention and intervention. Histopathological diagnosis continues to be the gold standard or the reference standard applied for efficacious diagnosis and treatment of cancer. The increasing burden of cancer across the world, together with the current shortage of expert and trained pathologists, presents a compelling need for new measures that can speed up both the accuracy and the speed of diagnosis.(2) The trajectory of artificial intelligence (AI) and deep learning (DL) are currently transforming the discipline of digital pathology in significant ways. AI possesses a remarkable capacity to systematically review gargantuan amounts of high-resolution whole-slide images (WSIs) and is also capable of identifying subtle patterns that tend to escape the human eye. This

technology holds a remarkable potential for significantly enhancing and supplementing the pathologist's diagnostic effort.(3)

The increased deployment of artificial intelligence (AI) continues to uncover excellent prospects for re-fashioning and enhancement of the environment of cancer diagnosis. With estimates suggesting that cases of cancer may almost double by 2035, especially in the low- and middle-income economies, the need for advanced and effective diagnostic processes is higher than ever before. AI-powered algorithms, like convolutional neural networks (CNNs), have been found to possess phenomenal accuracy in tumor type classification and discrimination between benign and malignant lesions. These developments not only simplify some of the diagnostic challenges to pathologists but also yield more accurate and targeted clinical decision-making processes.(4)

The use of AI in clinical oncology diagnosis has increased robustly over the years, with applications such as primary tumor detection, metastasis assessment, prognostication modeling, and biomarker prediction. Aside from raw performance metrics, the successful use of AI in pathology also relies on reproducibility, clinical interpretability, and infrastructure compatibility. In this review, we synthesize findings from heterogeneous sources—initial research studies comparing AI models in prostate, breast, and skin cancers, as well as more general reviews of deep learning in tumor pathology and reproducibility frameworks—to provide an integrated narrative of AI's clinical effectiveness, technical underpinnings, and future promise.

2. The role of Artificial intelligence

AI is revolutionizing the diagnosis of cancer through effective and precise analysis of large data sets. It makes earlier detection possible, which is a key factor in improved outcomes. AI assists radiologists in the automation of imaging interpretation. Machine learning improves the accuracy of tumor detection through the combination of molecular and histopathological information. This decreases oncological data processing time, allowing physicians to focus on fine diagnostic and treatment choices.(5)

Perhaps the most exciting advance in this field is the use of AI for the pre-symptomatic detection of tumors, a long-standing problem in oncology. With imaging modalities generating ever more sophisticated and extensive data, older analytical methods are increasingly inadequate. By contrast, AI can quickly examine and analyze these images, detecting faint anomalies and patterns that may elude the human eye. This prognostic capability makes AI a central tool in clinical research, with the capacity to enable cancer detection by imaging as well as through the incorporation of genomic data. Continued advances in AI technologies should provide even more advanced algorithms, ultimately leading to breakthroughs in early diagnosis of cancer, treatment protocol customization, and overall remaking of oncological practice.(6)

3. Clinical Accuracy and Diagnostic Enhancement:

The use of AI in digital pathology has shown steady improvements in diagnostic accuracy for various types of tumors. In the case of prostate cancer, AI algorithms learned from WSIs of core needle biopsies have indicated the ability to classify slides into "suspicious" or "not suspicious" with a sensitivity rate higher than 90%, which is comparable to expert genitourinary pathologists. (7) These systems can be employed as prescreening tools, helping to rule out benign cases and flagging potential malignancies for detailed review. Such usage not only improves diagnostic accuracy but also streamlines clinical workflows by reducing the number of slides requiring manual evaluation. (8)

In breast cancer diagnostics, sentinel lymph node (SLN) evaluation is critical for staging and treatment decisions. AI integration into SLN assessment, as demonstrated in real-world clinical studies, has yielded substantial improvements in both sensitivity and efficiency. AI-assisted workflows enabled the detection of micro-metastases with significantly greater accuracy compared to traditional methods while reducing the time pathologists spent per case by 40%. Furthermore, unnecessary use of immunohistochemistry (IHC) a time and resource intensive procedure was curtailed by nearly one-third, illustrating the technology's cost-saving potential. (9)

Similarly, the deployment of AI in dermatology, particularly for melanoma detection, reveals promising performance. In prospective multicenter studies, deep learning models applied to dermoscopic images captured with consumer-grade devices achieved area under the receiver operating characteristic curve (AUROC) values above 95%. Even at thresholds ensuring 100% sensitivity, these models maintained clinically acceptable specificity, reinforcing their utility as triage tools in primary care or resource-limited settings. These results underscore the potential of AI to democratize access to high-quality diagnostic capabilities in regions lacking specialized expertise. (10)

Workflow Stage	Traditional Process	With AI Integration	Impact
Image Screening	Manual by radiologist	AI Pre-screening	Faster triage
Diagnosis	Human interpretation	AI-assisted review	Reduced errors
Reporting	Typed reports	AI-generated templates	Time saving
Follow-up Planning	Physician-led	AI-supported predictions	More personalized care

Table 1: Workflow impact of AI(11)

4. Broader Utility in Tumor Pathology:

Beyond single-disease applications, deep learning systems are being leveraged for broader pathology tasks including tumor subtyping, grading, biomarker prediction, and prognosis estimation. Convolutional neural networks (CNNs) and other deep learning architectures have been trained to distinguish between cancer subtypes, such as adenocarcinoma versus squamous cell carcinoma, with AUCs ranging from 0.83 to 0.97. In breast, lung, ovarian, and thyroid cancers, these distinctions are crucial for tailoring treatment strategies. (12)

AI tools have also been validated for the quantification of histological features like mitotic figures, tumor budding, immune infiltration, and proliferative indices (e.g., Ki-67). In some studies, AI-derived metrics not only matched but outperformed traditional methods in prognostic accuracy. The ability of certain DL models to infer genetic mutations such as TP53 or EGFR status from standard hematoxylin and eosin (H&E) slides represents a major stride toward precision oncology. Such insights, when integrated with clinical and molecular data, may enable more holistic and individualized treatment planning.

5. Reproducibility and Model Validation:

While AI’s diagnostic power is evident, reproducibility across institutions and datasets remains a pivotal concern. One of the significant contributions to this domain is the DAPPER framework, an open-source pipeline that standardizes the assessment of model repeatability. Inspired by regulatory initiatives like the FDA’s MAQC project, DAPPER applies rigorous validation protocols, including repeated cross-validation and the use of public benchmark datasets like HINT, to test the stability of features extracted via deep learning models. (13)

This framework combines CNN-based feature extraction with traditional machine learning classifiers (e.g., random forests, SVMs) and reports performance with detailed statistical robustness. External validation against the KIMIA24 dataset further confirmed DAPPER-trained models’ generalizability. Such initiatives are vital for fostering clinical trust and paving the way toward regulatory approval of AI-based diagnostic tools.

Figure 1. DAPPER Framework Implementation




6. Workflow Efficiency and Integration:

AI-enhanced workflows offer tangible improvements in diagnostic throughput. In pathology departments strained by high caseloads and limited personnel, AI support can alleviate bottlenecks. Studies have shown that AI systems can halve the time required for case review, particularly in routine evaluations such as negative biopsy screening or SLN assessments. The reduced reliance on ancillary techniques like IHC, along with fewer unnecessary biopsies, contributes to a more efficient use of resources. (14)

Successful integration, though, requires close attention to interoperability and clinician usability. AI systems need to be integrated into digital pathology platforms in a way that supports and doesn't disrupt workflows. Clinician-friendly interfaces, ongoing model retraining, and clinician monitoring are essential factors for guaranteeing that AI is utilized as an assistive tool and not a disruptor. Pathologist-AI feedback loops also improve model refinement and diagnostic confidence. (15)

Figure 2. Pros and Cons of AI in Pathology



7. Limitations, Challenges, and Ethical Considerations:

One of the largest challenges to adoption is the lack of adequate external validation of the systems. The majority of studies are based on single-institution data, which have limited demographic heterogeneity; this may potentially limit the generalizability of results to patient populations with diverse demographics. Additionally, the interpretability of deep learning models, which are typically vilified as "black boxes," presents another level of challenge to the problem. Pathologists and clinicians need to be able to interpret and trust the results generated by these models, especially when high-stakes decisions are made that can potentially have a significant contribution to patient care.(16)

In addition, it is critical to exercise careful attention to ethical concerns of data privacy, algorithmic bias, and the highest priority of fair access to healthcare services, as these all must be fully addressed. To avoid worsening existing health disparities, it is critical that training data utilized is representative and diverse for multiple populations. Regulatory bodies have begun to release guidelines and recommendations; however, the development of harmonized worldwide guidelines and reimbursement systems is still in its infancy and needs further development. Lastly, it is critical to recognize that there is considerable cultural physician resistance to the adoption of such sophisticated technology, which necessitates the deployment of educational modules as well as the creation of open medico-legal frameworks to ensure accountability and promote transparency of AI-assisted diagnoses.

8. Future Directions:

To realize the full potential of AI in oncology diagnostics, future efforts should focus on several key domains:

- Expansion of multicenter validation studies with diverse populations.
- Development of interpretable and explainable AI models.
- Establishment of universal benchmarks and performance metrics.
- Integration of multimodal data, including genomics and radiomics.
- Seamless inclusion in clinical guidelines, educational curricula, and electronic health records.

Additionally, collaboration between AI developers, clinicians, regulators, and ethicists will be essential for aligning technical innovation with patient-centered care. Ensuring transparency, accountability, and accessibility will determine AI’s success as a transformative tool in modern oncology.

9. Conclusion:

Artificial intelligence is increasingly a trusted partner in the war on cancer with the potential for more accurate diagnosis, streamlining of workflows, and reproducibility. AI systems have demonstrated clinical utility in a variety of settings in prostate and breast cancer, melanoma, and others. DAPPER is one example that illustrates the need for stringent validation, and applications in tumor pathology show the promising role of scaling information with AI. As the technology advances, judicious integration of these innovations—achieve a seamless blend of automation and human ingenuity—will be the solution. AI, when it is managed well, has the potential to improve the accuracy, efficiency, and equity of cancer diagnosis for patients across the globe.

References:

Ramesh P, Karuppasamy R, Veerappapillai SJB. A review on recent advancements in diagnosis and classification of cancers using artificial intelligence. 2020;10(3):5.

- Iqbal MJ, Javed Z, Sadia H, Qureshi IA, Irshad A, Ahmed R, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. 2021;21(1):270.
- Sudha B, Suganya K, Swathi K, Sumathi S. Artificial Intelligence is Revolutionizing Cancer Research. Machine Learning and Deep Learning Techniques for Medical Science: CRC Press; 2022. p. 263-78.
- Elemento O, Leslie C, Lundin J, Tourassi GJNRC. Artificial intelligence in cancer research, diagnosis and therapy. 2021;21(12):747-52.
- Bharati S, Podder P, Mondal MJapa. Artificial neural network based breast cancer screening: a comprehensive review. 2020.
- Tiwari A, Mishra S, Kuo T-RJMC. Current AI technologies in cancer diagnostics and treatment. 2025;24(1):159.
- Rabaan AA, Bakhrebah MA, AlSaihati H, Alhumaid S, Alsubki RA, Turkistani SA, et al. Artificial intelligence for clinical diagnosis and treatment of prostate cancer. Cancers. 2022;14(22):5595.
- Patel AU, Mohanty SK, Parwani AV. Applications of digital and computational pathology and artificial intelligence in genitourinary pathology diagnostics. Surgical Pathology Clinics. 2022;15(4):759-85.
- van Doijeweert C, Flach R, Ter Hoeve N, Vreuls C, Goldschmeding R, Freund J, et al. Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial. Nature Cancer. 2024;5(8):1195-205.
- Phillips M, Marsden H, Jaffe W, Matin RN, Wali GN, Greenhalgh J, et al. Assessment of accuracy of an artificial intelligence algorithm to detect melanoma in images of skin lesions. JAMA network open. 2019;2(10):e1913436.
- Yacoub B, Varga-Szemes A, Schoepf UJ, Kabakus IM, Baruah D, Burt JR, et al. Impact of artificial intelligence assistance on chest CT interpretation times: a prospective randomized study. 2022;219(5):743-51.
- Jiang Y, Yang M, Wang S, Li X, Sun Y. Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer communications. 2020;40(4):154-66.
- Bizzego A, Bussola N, Chierici M, Maggio V, Francescatto M, Cima L, et al. Evaluating reproducibility of AI algorithms in digital pathology with DAPPER. PLoS computational biology. 2019;15(3):e1006269.
- Jarrahi MH, Davoudi V, Haeri M. The key to an effective AI-powered digital pathology: Establishing a symbiotic workflow between pathologists and machine. Journal of pathology informatics. 2022;13:100156.
- Georgescu W, Saligrama K, Luna C, Lawler D, Lacey C. Artificial intelligence processing system and automated pre-diagnostic workflow for digital pathology. Google Patents; 2022.
- Bizzego A, Bussola N, Chierici M, Maggio V, Francescatto M, Cima L, et al. Evaluating reproducibility of AI algorithms in digital pathology with DAPPER. 2019;15(3):e1006269.